PDCD1 and glioblastoma: In this study, we developed a method to equip OVs with ROS-responsive anti-PD-1 and alendronate coatings (PD-1/Al@OV), thereby enhancing T cell activity and preventing OV engulfment by TAMs to improve therapeutic efficacy against GBM (Fig. 1).